Edwards rose 1.5% after reporting third-quarter sales growth of 11.2% and raising full-year sales and adjusted EPS guidance. The move was within ±3%, so the reaction was relatively muted despite management’s positive characterization of the quarter.
Edwards Lifesciences shares declined 2.1% following Q2 earnings, reflecting cautious investor response despite solid sales growth, as the market weighed lingering uncertainties regarding margin expansion and long-term growth visibility.
Edwards Lifesciences delivered strong Q3 2025 results with 12.6% sales growth, driven by a comprehensive portfolio in structural heart therapies, prompting an upward revision of full-year guidance for sales and EPS.